GEN Exclusives

More »

GEN News Highlights

More »
Mar 19, 2008

NicOx Signs On Archimica as Commercial Supplier of Phase III Osteoarthritis Therapeutic

  • NicOx signed an agreement with Archimica for the commercial manufacturing and supply of naproxcinod. The compound is in Phase III studies for osteoarthritis.

    The goal is to secure commercial-scale quantities to ensure the successful launch of naproxcinod. NicOx expects to file an NDA in mid-2009. Archimica will supply naproxcinod API from its Springfield, MO, facility. NicOx says that the first deliveries of significant quantities of commercial material should be made from the fourth quarter of 2009 onwards. The firm adds that it may add two additional suppliers.

    Naproxcinod is NicOx' lead investigational product and belongs to the COX-inhibiting nitric oxide-donating class of anti-inflammatory agents. The Phase III trials are designed to demonstrate that it is safe, well tolerated, effective, and has no detrimental effect on blood pressure, in contrast to existing NSAIDs.

    While NicOx plans to retain commercialization rights in the U.S. and some EU countries, the company says that it will look for partners in other regions.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?